I. Critchley

发表

Effect of antibiotics on non-growing planktonic cells and biofilms of Escherichia coli.

S. J. Knott, M. Ashby, J. Neale, 1994, The Journal of antimicrobial chemotherapy.

FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.

C. Schumann, T. File, P. Eckburg, 2011, The Journal of antimicrobial chemotherapy.

Evaluation of Current Activities of Fluoroquinolones against Gram-Negative Bacilli Using Centralized In Vitro Testing and Electronic Surveillance

J. Karlowsky, D. Sahm, I. Critchley, 2001, Antimicrobial Agents and Chemotherapy.

Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking Resistance in the United States Today. The Surveillance Network.

A. Evangelista, J. Karlowsky, D. Sahm, 2002, International journal of antimicrobial agents.

Evolution of Ceftaroline-Resistant Mrsa in a Child with Cystic Fibrosis Following Repeated Antibiotic Exposure

Ronald N. Jones, D. Farrell, J. Le, 2016, The Pediatric infectious disease journal.

The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the United States in 2017

M. Pucci, R. Mendes, I. Critchley, 2019, bioRxiv.

The burden of antimicrobial resistance among urinary tract isolates of Escherichia coli in the United States in 2017

M. Pucci, R. Mendes, I. Critchley, 2019, PloS one.

Prevalence of antimicrobial resistance among urinary tract pathogens isolated from female outpatients across the US in 1999.

J. Karlowsky, M. Jones, D. Sahm, 2001, International journal of antimicrobial agents.

Dalbavancin Population Pharmacokinetic Modeling and Target Attainment Analysis

Jason T Chittenden, I. Critchley, T. Carrothers, 2019, Clinical pharmacology in drug development.

Decreased Ceftriaxone Susceptibility in Emerging (35B and 6C) and Persisting (19A) Streptococcus pneumoniae Serotypes in the United States, 2011-2012: Ceftaroline Remains Active In Vitro among β-Lactam Agents

Ronald N. Jones, D. Farrell, H. Sader, 2014, Antimicrobial Agents and Chemotherapy.

Eradication of MRSA nasal colonization as a strategy for infection prevention

I. Critchley, 2006 .

Dose Selection and Validation for Ceftazidime-Avibactam in Adults with Complicated Intra-abdominal Infections, Complicated Urinary Tract Infections, and Nosocomial Pneumonia

T. Riccobene, Jianguo Li, I. Critchley, 2019, Antimicrobial Agents and Chemotherapy.

Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa

T. Riccobene, I. Critchley, Shampa Das, 2018, Antimicrobial Agents and Chemotherapy.

Assessment of 30/20-Microgram Disk Content versus MIC Results for Ceftazidime-Avibactam Tested against Enterobacteriaceae and Pseudomonas aeruginosa

Ronald N. Jones, M. Huband, P. Rhomberg, 2018, Journal of Clinical Microbiology.

Isolation and partial characterization of an adhesin from Candida albicans.

L. J. Douglas, I. Critchley, 1987, Journal of general microbiology.

Mechanism of adherence of Candida albicans to epithelial cells

I. Critchley, 1986 .

Mode of Action and Biochemical Characterization of REP8839, a Novel Inhibitor of Methionyl-tRNA Synthetase

F. Dean, N. Janjić, U. Ochsner, 2005, Antimicrobial Agents and Chemotherapy.

States 377 Medical Centers throughout the United against Recent Respiratory Isolates from Moxifloxacin and Comparator Agents Benchmarking the In Vitro Activities of

E. Jones, I. Critchley, H. D. Engler, 2014 .

Molecular Characterization of Vancomycin-Resistant Enterococci Repopulating the Gastrointestinal Tract following Treatment with a Novel Glycolipodepsipeptide, Ramoplanin

G. Eliopoulos, S. Porter, R. Moellering, 2002, Journal of Clinical Microbiology.

Longitudinal Assessment of Antipneumococcal Susceptibility in the United States

J. Karlowsky, D. Sahm, I. Critchley, 2002, Antimicrobial Agents and Chemotherapy.

Need for Annual Surveillance of Antimicrobial Resistance in Streptococcus pneumoniae in the United States: 2-Year Longitudinal Analysis

J. Karlowsky, D. Sahm, I. Critchley, 2001, Antimicrobial Agents and Chemotherapy.

Benchmarking the In Vitro Activities of Moxifloxacin and Comparator Agents against Recent Respiratory Isolates from 377 Medical Centers throughout the United States

D. Sahm, I. Critchley, Mark E. Jones, 2000, Antimicrobial Agents and Chemotherapy.

Benchmarking the in vitro activity of moxifloxacin against recent isolates of Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae. A European multi-centre study.

M. Jones, D. Sahm, I. Critchley, 2000, Diagnostic microbiology and infectious disease.

Effect of In Vitro Testing Parameters on Ceftazidime-Avibactam Minimum Inhibitory Concentrations

K. Krause, I. Critchley, D. Biek, 2015, International scholarly research notices.

In Vitro Activities of Novel Nonfluorinated Quinolones PGE 9262932 and PGE 9509924 against Clinical Isolates of Staphylococcus aureus and Streptococcus pneumoniae with Defined Mutations in DNA Gyrase and Topoisomerase IV

J. Karlowsky, D. Sahm, I. Critchley, 2002, Antimicrobial Agents and Chemotherapy.

Avibactam Pharmacokinetic/Pharmacodynamic Targets

T. Riccobene, I. Critchley, Shampa Das, 2018, Antimicrobial Agents and Chemotherapy.

The effects of adherence to silicone surfaces on antibiotic susceptibility in Staphylococcus aureus.

D. Lloyd, I. Critchley, W. A. Venables, 1997, Microbiology.

FOCUS 2: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia.

J. Milanowski, T. File, D. Górecka, 2011, The Journal of antimicrobial chemotherapy.

New agents for Clostridium difficile-associated disease

I. Critchley, J. Guiles, Xicheng Sun, 2008, Expert opinion on investigational drugs.

Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections.

T. Jarvis, N. Janjić, U. Ochsner, 2009, The Journal of antimicrobial chemotherapy.

Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model.

N. Janjić, U. Ochsner, I. Critchley, 2009, The Journal of antimicrobial chemotherapy.

Ceftazidime–avibactam for the treatment of complicated urinary tract infections and complicated intra-abdominal infections

T. Riccobene, I. Critchley, Y. Mawal, 2015, Expert review of clinical pharmacology.

In Vitro Resistance against DNA Gyrase Inhibitor SPR719 in Mycobacterium avium and Mycobacterium abscessus

T. Dick, M. Gengenbacher, M. Pucci, 2022, Microbiology spectrum.

In Vitro and In Vivo Characterization of Tebipenem, an Oral Carbapenem

A. Rubio, M. Pucci, I. Critchley, 2020, Antimicrobial Agents and Chemotherapy.

Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000.

A. Evangelista, J. Karlowsky, D. Sahm, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Baseline Study To Determine In Vitro Activities of Daptomycin against Gram-Positive Pathogens Isolated in the United States in 2000-2001

J. Karlowsky, D. Sahm, I. Critchley, 2003, Antimicrobial Agents and Chemotherapy.

Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002).

A. Evangelista, J. Karlowsky, D. Sahm, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001.

J. Karlowsky, D. Sahm, I. Critchley, 2003, The Journal of antimicrobial chemotherapy.

Phenotypic and genotypic analysis of levofloxacin-resistant clinical isolates of Streptococcus pneumoniae collected in 13 countries during 1999-2000.

J. Karlowsky, D. Sahm, I. Critchley, 2002, International journal of antimicrobial agents.

Antimicrobial susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in two successive respiratory seasons in the US.

J. Karlowsky, D. Sahm, I. Critchley, 2002, International journal of antimicrobial agents.

Activity of Ceftaroline and Epidemiologic Trends in Staphylococcus aureus Isolates Collected from 43 Medical Centers in the United States in 2009

S. Richter, G. Doern, D. Diekema, 2011, Antimicrobial Agents and Chemotherapy.

Serotype distribution and antimicrobial susceptibility of USA Streptococcus pneumoniae isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccine.

Ronald N. Jones, M. Jacobs, R. Mendes, 2014, Diagnostic microbiology and infectious disease.

Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity.

T. Riccobene, I. Critchley, D. Thye, 2010, The Journal of antimicrobial chemotherapy.

Susceptibilities to Levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis Clinical Isolates from Children: Results from 2000-2001 and 2001-2002 TRUST Studies in the United States

G. Noel, A. Evangelista, J. Karlowsky, 2003, Antimicrobial Agents and Chemotherapy.

Antimicrobial susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis collected from five centers in Brazil, 1997-98.

M. Jones, D. Sahm, H. Sader, 2000, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Ceftaroline Activity Against Staphylococci and Characterization of S. aureus with Elevated Ceftaroline MIC Values: Results from the Ceftaroline Surveillance Program

H. Sader, I. Critchley, D. Biek, 2009 .

Antimicrobial susceptibilities of Streptococcus pyogenes isolated from respiratory and skin and soft tissue infections: United States LIBRA surveillance data from 1999.

J. Karlowsky, D. Sahm, I. Critchley, 2002, Diagnostic microbiology and infectious disease.

In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe.

A. Evangelista, J. Karlowsky, M. Jones, 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Apparent plateau in beta-lactamase production among clinical isolates of Haemophilus influenzae and Moraxella catarrhalis in the United States: results from the LIBRA Surveillance initiative.

J. Karlowsky, D. Sahm, I. Critchley, 2002, International journal of antimicrobial agents.

Analysis of Ciprofloxacin Activity against Streptococcus pneumoniae after 10 Years of Use in the United States

D. Sahm, I. Critchley, C. Thornsberry, 2000, Antimicrobial Agents and Chemotherapy.

Panton-Valentine Leukocidin Is Not the Primary Determinant of Outcome for Staphylococcus aureus Skin Infections: Evaluation from the CANVAS Studies

B. Sharma-Kuinkel, F. Ruffin, V. Fowler, 2012, PloS one.

Review of ceftaroline fosamil microbiology: integrated FOCUS studies.

P. Eckburg, I. Critchley, A. Jandourek, 2011, The Journal of antimicrobial chemotherapy.

In vitro susceptibility of recent clinical isolates of pneumococci to the investigational cephalosporin cefditoren.

J. Karlowsky, D. Sahm, I. Critchley, 2002, Diagnostic microbiology and infectious disease.

Antimicrobial susceptibility of 840 clinical isolates of Haemophilus influenzae collected in four European countries in 2000-2001.

J. Karlowsky, M. Jones, D. Sahm, 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Relationship between Antibiotic Resistance in Streptococcus pneumoniae and That in Haemophilus influenzae: Evidence for Common Selective Pressure

J. Karlowsky, D. Sahm, I. Critchley, 2002, Antimicrobial Agents and Chemotherapy.

Analysis of Daptomycin Efficacy and Breakpoint Standards in a Murine Model of Enterococcus faecalis and Enterococcus faecium Renal Infection

Donghui Yu, J. Alder, J. Silverman, 2003, Antimicrobial Agents and Chemotherapy.

Development of a standardized susceptibility test for campylobacter with quality-control ranges for ciprofloxacin, doxycycline, erythromycin, gentamicin, and meropenem.

F. Aarestrup, P. McDermott, L. Piddock, 2004, Microbial drug resistance.

Conventional laboratory agar media provide an iron-limited environment for bacterial growth

I. Critchley, M. Basker, 1988 .

Role of glycosides as epithelial cell receptors for Candida albicans.

L. J. Douglas, I. Critchley, 1987, Journal of general microbiology.

Differential adhesion of pathogenic Candida species to epithelial and inert surfaces

L. J. Douglas, I. Critchley, 1985 .

Invitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe

A. Evangelista, J. Karlowsky, M. Jones, 2014 .

Activity of faropenem, a new furanem, against European respiratory pathogens collected during 2000-2001: a comparison with other beta-lactam agents.

J. Karlowsky, D. Sahm, I. Critchley, 2003, The Journal of antimicrobial chemotherapy.

Activity of Ceftaroline Against Recent Emerging Serotypes of Streptococcus 1

Ronald N. Jones, M. Jacobs, H. Sader, 2010 .

In Vitro Antimicrobial Activity of GSQ1530, a New Heteroaromatic Polycyclic Compound

R. Bürli, I. Critchley, H. Moser, 2002, Antimicrobial Agents and Chemotherapy.

Activity of faropenem tested against Neisseria gonorrhoeae isolates including fluoroquinolone-resistant strains.

Ronald N. Jones, N. Janjić, W. Whittington, 2005, Diagnostic microbiology and infectious disease.

Activities of Faropenem, an Oral β-Lactam, against Recent U.S. Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis

J. Karlowsky, D. Sahm, I. Critchley, 2002, Antimicrobial Agents and Chemotherapy.

Antimicrobial Activity of Ceftaroline Tested Against Streptococci from United States (USA) and European (EU) Medical Centers: Results from the Ceftaroline Surveillance Program

Ronald N. Jones, I. Critchley, D. Biek, 2009 .

Determining Linezolid’s Baseline In Vitro Activity in Canada Using Gram-Positive Clinical Isolates Collected prior to Its National Release

J. Karlowsky, D. Sahm, I. Critchley, 2002, Antimicrobial Agents and Chemotherapy.

Quinazolin-2-ylamino-quinazolin-4-ols as novel non-nucleoside inhibitors of bacterial DNA polymerase III.

F. Dean, N. Janjić, U. Ochsner, 2009, Bioorganic & medicinal chemistry letters.

Oral Tebipenem Pivoxil Hydrobromide in Complicated Urinary Tract Infection.

P. Eckburg, A. Dane, I. Critchley, 2022, The New England journal of medicine.

In vitro Synergy Studies Using Aztreonam and Fluoroquinolone Combinations against Six Species of Gram-Negative Bacilli

J. Karlowsky, D. Sahm, I. Critchley, 2003, Chemotherapy.

In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000-2001.

J. Karlowsky, M. Jones, D. Sahm, 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Microbiological Profile of Sarecycline, a Novel Targeted Spectrum Tetracycline for the Treatment of Acne Vulgaris

G. Zhanel, I. Critchley, Lynn-Yao Lin, 2018, Antimicrobial Agents and Chemotherapy.

Resistance among urinary tract pathogens collected in Europe during 2018.

M. Pucci, R. Mendes, I. Critchley, 2020, Journal of global antimicrobial resistance.

Optimal use of antibiotic resistance surveillance systems.

J. Karlowsky, I. Critchley, 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Activity of chequerboard combinations of ceftaroline and NXL104 versus beta-lactamase-producing Enterobacteriaceae.

D. Livermore, G. Williams, M. Warner, 2010, The Journal of antimicrobial chemotherapy.

Comparative Activity of Cefditoren and Other Oral β-Lactams against Nonpneumococcal Streptococci

J. Karlowsky, D. Sahm, I. Critchley, 2001, Chemotherapy.

Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection.

M. Wilcox, G. Witherell, G. Talbot, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antimicrobial Surveillance of Haemophilus influenzae in the United States during 2000-2001 Leads to Detection of Clonal Dissemination of a β-Lactamase-Negative and Ampicillin-Resistant Strain

J. Karlowsky, D. Sahm, I. Critchley, 2002, Journal of Clinical Microbiology.

Studies on the interaction of staphylococcus aureus and staphylococcus epidermidis with fibronectin using surface plasmon resonance (BIAcore)

Stephen D Holmes, I. Critchley, F. Markey, 1997 .

Pharmacodynamics of β-Lactamase Inhibition by NXL104 in Combination with Ceftaroline: Examining Organisms with Multiple Types of β-Lactamases

Ronald N. Jones, M. Castanheira, G. Drusano, 2011, Antimicrobial Agents and Chemotherapy.

National and Regional Assessment of Antimicrobial Resistance among Community-Acquired Respiratory Tract Pathogens Identified in a 2005-2006 U.S. Faropenem Surveillance Study

N. Janjić, Steven D. Brown, G. Tillotson, 2007, Antimicrobial Agents and Chemotherapy.

Recent advances in the preclinical evaluation of the topical antibacterial agent REP8839.

U. Ochsner, I. Critchley, 2008, Current opinion in chemical biology.

Aminoacyl-tRNA synthetases: essential and still promising targets for new anti-infective agents

Ian Critchley, Nebojsa Janjic, T. Jarvis, 2007, Expert opinion on investigational drugs.

Antibacterial Activity of REP8839, a New Antibiotic for Topical Use

N. Janjić, U. Ochsner, I. Critchley, 2005, Antimicrobial Agents and Chemotherapy.

Inhibitor of Methionyl-tRNA Synthetase Characterization of REP 8839 , a Novel Mode of Action and Biochemical

F. Dean, N. Janjić, U. Ochsner, 2005 .

Pharmacodynamics of Tebipenem: New Options for Oral Treatment of Multidrug-Resistant Gram-Negative Infections

A. Dane, J. Unsworth, P. Ambrose, 2019, Antimicrobial Agents and Chemotherapy.

International Surveillance of Susceptibility to Levofloxacin and Other Agents among Respiratory Pathogens

M. Jones, D. Sahm, I. Critchley, 1999, Drugs.

Evaluation of Pneumococci From the United States (USA) Pediatric Patients Isolated During the 2009 AWARE Program

K. Krause, H. Sader, I. Critchley, 2011 .

Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia.

T. File, P. Eckburg, D. Low, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Susceptibility of Staphylococcus aureus isolated from skin and wound infections in the United States 2005-07: laboratory-based surveillance study.

G. Tillotson, D. Sahm, I. Critchley, 2008, The Journal of antimicrobial chemotherapy.

Activity of cefditoren against beta-lactamase-positive and -negative Haemophilus influenzae and Moraxella catarrhalis.

J. Karlowsky, D. Sahm, I. Critchley, 2002, Diagnostic microbiology and infectious disease.

Prevalence of Serotype 19A Streptococcus pneumoniae among Isolates from U.S. Children in 2005-2006 and Activity of Faropenem

Michael R. Jacobs, Nebojsa Janjic, N. Janjić, 2008, Antimicrobial Agents and Chemotherapy.

Accuracy of the Thermo Fisher Scientific (Sensititre™) dry-form broth microdilution MIC product when testing ceftaroline.

Ronald N. Jones, I. Critchley, N. Holliday, 2015, Diagnostic microbiology and infectious disease.

Activity of Ceftaroline against Recent Emerging Serotypes of Streptococcus pneumoniae in the United States

Ronald N. Jones, Michael R. Jacobs, Helio S. Sader, 2010, Antimicrobial Agents and Chemotherapy.

Flow cytometry and other techniques show that Staphylococcus aureus undergoes significant physiological changes in the early stages of surface-attached culture.

P. Randerson, D. Lloyd, A. Hayes, 1999, Microbiology.

Bactericidal Activity of Ceftaroline Combined with NXL104 Against Critical Targeted Organisms Possessing Various Resistance Mechanisms

M. Castanheira, I. Critchley, Gregory C. Williams, 2009 .

Fosfomycin and Comparator Activity Against Select Enterobacteriaceae, Pseudomonas, and Enterococcus Urinary Tract Infection Isolates from the United States in 2012

K. Krause, I. Critchley, D. Biek, 2017, Infectious Diseases and Therapy.

Evaluation of Tebipenem Hydrolysis by β-Lactamases Prevalent in Complicated Urinary Tract Infections

T. Palzkill, M. Pucci, I. Critchley, 2022, Antimicrobial Agents and Chemotherapy.

Randomized Trial of Ceftazidime-Avibactam vs Meropenem for Treatment of Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (REPROVE): Analyses per US FDA–Specified End Points

A. Torres, T. Riccobene, H. Lakkis, 2019, Open forum infectious diseases.

The Activity of Levofloxacin and Comparator Agents against Clinical Isolates of Streptococcus pneumoniae Collected Worldwide during 1999 and 2000

J. Karlowsky, D. Sahm, I. Critchley, 2002, Chemotherapy.

Proficiency of Italian clinical laboratories in detecting reduced glycopeptide susceptibility in Enterococcus and Staphylococcus spp. using routine laboratory methodologies.

A. Goglio, D. Sahm, G. Gesu, 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

Contemporary Evaluation of Tebipenem In Vitro Activity against Enterobacterales Clinical Isolates Causing Urinary Tract Infections in US Medical Centers (2019–2020)

M. Castanheira, R. Mendes, I. Critchley, 2023, Microbiology spectrum.

In Vitro Activity of Tebipenem against Various Resistant Subsets of Escherichia coli Causing Urinary Tract Infections in the United States (2018 to 2020)

M. Castanheira, R. Mendes, I. Critchley, 2022, Antimicrobial agents and chemotherapy.

Agar Dilution and Disk Diffusion Susceptibility Testing of Campylobacter spp.

Ronald N. Jones, F. Aarestrup, L. Piddock, 2007 .

1036. In Vitro Analysis of AmpC β-lactamase Induction by Tebipenem in Enterobacterales and Pseudomonas aeruginosa

M. Castanheira, R. Mendes, I. Critchley, 2021, Open Forum Infectious Diseases.

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Evaluate In Vitro Susceptibility Test Interpretive Criteria for Ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae

T. Riccobene, S. Bhavnani, P. Ambrose, 2013, Antimicrobial Agents and Chemotherapy.

Quinazolin-2-ylamino-quinazolin-4-ols as novel non-nucleoside inhibitors of bacterial DNA polymerase III.

F. Dean, N. Janjić, U. Ochsner, 2009, Bioorganic & medicinal chemistry letters.

Phase 3, Randomized, Double-blind Noninferiority (NI) Study of Ceftazidime–Avibactam (CAZ-AVI) vs. Meropenem (MER) in the Treatment of Patients with Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP): Analyses of the REPROVE Study per US FDA Endpoints

A. Torres, T. Riccobene, H. Lakkis, 2017 .

Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections.

T. Jarvis, N. Janjić, U. Ochsner, 2009, The Journal of antimicrobial chemotherapy.

Uptake of a catecholic cephalosporin by the iron transport system of Escherichia coli.

S. J. Knott, I. Critchley, M. Basker, 1991, The Journal of antimicrobial chemotherapy.

M. Wilcox, G. Talbot, Anita F. Das, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Avibactam Pharmacokinetic/Pharmacodynamic Targets

T. Riccobene, I. Critchley, Shampa Das, 2018, Antimicrobial Agents and Chemotherapy.

Activity of Faropenem against Middle Ear Fluid Pathogens from Children with Acute Otitis Media in Costa Rica and Israel

E. Wang, N. Janjić, R. Dagan, 2007, Antimicrobial Agents and Chemotherapy.

1676. Activity of SPR206 and Comparator Agents Against Pseudomonas aeruginosa and Acinetobacter baumannii Causing Infections in United States Hospitals

M. Castanheira, H. Sader, R. Mendes, 2022, Open Forum Infectious Diseases.

The Activity of Fluoroquinolones and Other Antimicrobial Agents Against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis

D. Sahm, I. Critchley, Mark E. Jones, 1999, Drugs.